This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
September quarter: consolidated revenue rises 61%, but losses and debt risk persist
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 September 2026: revenue rose 61.2% to Rs 7,939.24 lakh from Rs 4,926.05 lakh a year earlier, but net loss was Rs 729.34 lakh versus Rs 1,185.44 lakh. Standalone quarter: revenue Rs 7,839.24 lakh; loss Rs 720.93 lakh. Bank dues of Rs 5,556.52 lakh were classified non-performing, including a Rs 2,671.57 lakh Bank of Baroda demand notice. Auditors flagged going-concern uncertainty, but the opinion was unmodified.
Revenue growth helps, but losses, non-performing debt and doubts about continued operations raise refinancing risk and may pressure the share price.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹79.39 Cr | ₹106.9 Cr | −25.7% |
| Operating profit | −₹9.16 Cr | −₹25.49 Cr | loss narrowed |
| Profit after tax | −₹7.21 Cr | −₹21.14 Cr | loss narrowed |
| EBITDA margin | -1.4% | -6.8% | +5.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.